Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

8. Estimates for the Distribution segment remain unchanged.

Research and development investment for 2008 is expected to be approximately $160 million. Selling, general and administrative expenses for 2008 are expected to be between $420 and $440 million. Amortization expense for 2008 is expected to be approximately $80 million.

Watson estimates adjusted earnings per diluted share will be between $1.90 and $2.00 and has increased its estimates for GAAP earnings per diluted share to between $1.90 and $2.00.

In 2008, the Company expects to incur pre-tax costs associated with the planned closure of its Carmel, NY manufacturing facilities of approximately $30 million which includes accelerated depreciation, severance, retention and other related plant closure costs. The Company also expects to incur $8.5 million of licensing costs. These and other charges are offset by the sales milestone from Barr Pharmaceuticals, the divestiture of the Company's interest in Somerset Pharmaceuticals, Inc. and the resolution of an Internal Revenue Service audit, and are excluded from Watson's 2008 adjusted earnings per diluted share forecast as detailed in Table 6 below.

Excluding special items as detailed in the EBITDA reconciliation Table 7 below, adjusted EBITDA is expected to be between $551 and $571 million.

Webcast and Conference Call Details

Watson will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time to discuss second quarter 2008 results, the outlook for 2008 and recent corporate developments. The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573. A taped replay of the call will be available by calling (800) 642-1687 with access pass code 56190878. The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code. This replay will remain in effect until midnight Eastern Daylight Time, August 15, 2008. To access the l
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... often have it that American Indians largely were wiped ... influenza and tuberculosis brought to the New World by ... 20 million people lived in the Americas shortly before ... killed by European diseases., But new research led by ... Johannes Krause of the University of Tubingen in Germany ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... 2014  Decision Resources Group finds that the vascular access device ... , India and China ... equal to the size of the United States ... experience much faster growth as a result of strong economic expansion, ... key findings from Decision Resources Group,s coverage of the BRIC vascular ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3Neurotrope To Host Conference Call 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... Using bacteria to generate energy is a signifiant step ... University of East Anglia (UEA). Published today by ... Academy of Sciences (PNAS), the research demonstrates for ... proteins which enable bacterial cells to transfer electrical charge. ...
... 23, 2011 DATATRAK International, Inc. (OTCQX: DATA), a ... for the clinical trials industry, today announced the Company,s ... for the second consecutive year. "Being ... the hard work and dedication DATATRAK and its employees ...
... In the computer displays of medical equipment in hospitals ... major role. But a discovery reported from the University ... which have been found to change their ordering and ... low concentrations of a particular bacterial lipid, might find ...
Cached Biology Technology:Discovery opens the door to electricity from microbes 2DATATRAK Recognized as 2011 Crain's Leading EDGE Award Winner 2Liquid crystal droplets discovered to be exquisitely sensitive to an important bacterial lipid 2Liquid crystal droplets discovered to be exquisitely sensitive to an important bacterial lipid 3
(Date:8/20/2014)... Ore. -- When are athletes who have suffered concussions ... Oregon study has found that high school athletes who ... 60 days experience a significant regression in their abilities ... The regression, as seen in changes in their balance ... 19 athletes. Ten of the 12 had returned to ...
(Date:8/20/2014)... a burning spiciness that is irresistible to some, but ... are using their findings to develop a new drug ... caused by inflammation or other problems. They reported their ... clinical trials, in ACS, Journal of Medicinal Chemistry ... ago, scientists had pegged a compound called capsaicin as ...
(Date:8/20/2014)... chairs, synthetic rugs and plastic bags could one day ... rather than petroleum, scientists are now reporting. The novel ... the world deal with its agricultural and plastic waste ... , Athanassia Athanassiou, Ilker S. Bayer and colleagues at ... popularity is constantly growing. In 2012, its production reached ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Today,s opening of a new breast health center next ... significant research opportunities for the Translational Genomics Research Institute ... will include a tumor biorepository for TGen that will ... to diagnose and treat breast cancer, which affects 1 ...
... the results are receiving rave reviews from apple lovers. ... a new apple cultivar has been introduced by scientists ... New Jersey, and Indiana experiment stations. This high-quality dessert ... S. Korban, of the Department of Natural Resources and ...
... GREECETo grow the high-quality potted plants preferred by ... affect plant growth and development. The use of ... production of compact gardenia plants; the chemicals are ... the production of lateral shoots that create aesthetically ...
Cached Biology News:Breast health center gives TGen new research opportunities 2Apple enthusiasts welcome WineCrisp 2Photoselective film proves effective for controlling height in potted gardenia plants 2
96 Well Base Plate...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
UGT1A7 (E-15)...
Biology Products: